Utsav Bali
@ubali1.bsky.social
“What I cannot create, I do not understand.”
― Richard P. Feynman
― Richard P. Feynman
Reposted by Utsav Bali
What’s happening with Moderna’s mRNA flu vaccine at the FDA is awful, but unfortunately typical:
An mRNA Refusal to File
www.science.org
February 11, 2026 at 9:46 PM
What’s happening with Moderna’s mRNA flu vaccine at the FDA is awful, but unfortunately typical:
Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
Eli Lilly reports strong Q4 2025 with $19.29B revenue, led by tirzepatide sales. Company expects $80-83B revenue in 2026, contrasting with Novo Nordisk's projected decline.
endpoints.news
February 4, 2026 at 2:20 PM
Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
Mapping the Genetics of Brown Fat www.insitro.com/news/mapping...
Mapping the Genetics of Brown Fat - insitro
How insitro unlocked population-scale human genetics in a tissue that has resisted measurement for decades – and what it reveals about peripheral approaches to metabolic disease The Furnace We Couldn’...
www.insitro.com
February 3, 2026 at 4:34 AM
Mapping the Genetics of Brown Fat www.insitro.com/news/mapping...
Biopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.
endpoints.news/biopharma-se...
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.
endpoints.news/biopharma-se...
Biopharma Sentiment Index | Q1 2026
After four years of misery, the mood in biopharma strengthened meaningfully going into 2026, with across-the-board gains and early signs of a recovery that might finally stick.
endpoints.news
January 29, 2026 at 1:00 PM
Biopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.
endpoints.news/biopharma-se...
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.
endpoints.news/biopharma-se...
U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office | Science | AAAS www.science.org/content/arti...
U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office
A Science analysis reveals how many were fired, retired, or quit across 14 agencies
www.science.org
January 29, 2026 at 12:37 PM
U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office | Science | AAAS www.science.org/content/arti...
Eric Topol's post on 'The Lowdown on Low-Dose Aspirin for Primary Prevention'
erictopol.substack.com/p/the-lowdow...
erictopol.substack.com/p/the-lowdow...
The Lowdown on Low-Dose Aspirin for Primary Prevention
Pivotal Randomized Trials and Guidelines
erictopol.substack.com
January 19, 2026 at 10:28 AM
Eric Topol's post on 'The Lowdown on Low-Dose Aspirin for Primary Prevention'
erictopol.substack.com/p/the-lowdow...
erictopol.substack.com/p/the-lowdow...
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
www.biopharmadive.com/news/jpm26-b...
www.biopharmadive.com/news/jpm26-b...
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.
www.biopharmadive.com
January 16, 2026 at 4:03 PM
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
www.biopharmadive.com/news/jpm26-b...
www.biopharmadive.com/news/jpm26-b...
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
www.biospace.com/business/dea...
www.biospace.com/business/dea...
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
www.biospace.com
January 16, 2026 at 3:50 PM
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
www.biospace.com/business/dea...
www.biospace.com/business/dea...
Weight regain after cessation of medication for weight management: systematic review and meta-analysis www.bmj.com/content/392/...
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
Objectives To quantify and compare the rate of weight regain after cessation of weight management medications (WMMs) in adults with overweight or obesity.
Design Systematic review and meta-analysis.
...
www.bmj.com
January 15, 2026 at 10:20 AM
Weight regain after cessation of medication for weight management: systematic review and meta-analysis www.bmj.com/content/392/...
Reposted by Utsav Bali
Watch: At #JPM26, former drug regulator Richard Pazdur rings the alarm about politics at FDA
Full session: www.statnews.com/2026/01/13/j...
Full session: www.statnews.com/2026/01/13/j...
January 13, 2026 at 8:42 PM
Watch: At #JPM26, former drug regulator Richard Pazdur rings the alarm about politics at FDA
Full session: www.statnews.com/2026/01/13/j...
Full session: www.statnews.com/2026/01/13/j...
2026 pre JPM deal landscape is already heating up: www.linkedin.com/pulse/biotec...
Biotech on Fire: The Week Leading Into JPM 2026
Hello everyone! The early January vibe is traditionally shaped by JP Morgan Healthcare, but this year’s first week is unusually active, suggesting that maybe, afterall, 2026 could be a genuinely good ...
www.linkedin.com
January 9, 2026 at 4:47 PM
2026 pre JPM deal landscape is already heating up: www.linkedin.com/pulse/biotec...
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
www.gov.uk/government/n...?
www.gov.uk/government/n...?
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
Milestone deal secures UK’s medicines access for patients, with a wide range of groundbreaking new treatments to reach NHS front-line quicker.
www.gov.uk
December 3, 2025 at 5:45 AM
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
www.gov.uk/government/n...?
www.gov.uk/government/n...?
AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC institute.global/insights/pub...
AI-Native Biotech Is an Opportunity for UK Leadership and Growth
AI-Native Biotech Is an Opportunity for UK Leadership and Growth
institute.global
November 20, 2025 at 10:30 AM
AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC institute.global/insights/pub...
AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC
February 4, 2026 at 3:38 PM
AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC
Nxera lays off 15% of staff, pivots pipeline focus in profitability push www.fiercebiotech.com/biotech/nxer...
Nxera lays off 15% of staff, pivots pipeline focus in profitability push
Nxera Pharma plans to lay off | Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.
www.fiercebiotech.com
November 18, 2025 at 10:55 AM
Nxera lays off 15% of staff, pivots pipeline focus in profitability push www.fiercebiotech.com/biotech/nxer...
Nice perspective on the necessity of creating an ecosystem of innovation in the life sciences...
Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...
Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...
Bell Labs Wasn't Built in a Day. Or Two Years.
Rome is famous for persisting for centuries - and having not been built in a day. If you go there, then one of the most magnificent sites is...
omicsomics.blogspot.com
November 18, 2025 at 10:54 AM
Nice perspective on the necessity of creating an ecosystem of innovation in the life sciences...
Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...
Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...
Reposted by Utsav Bali
'The Evidence' on the BBC World Service where we discussed weight loss medications, which we recorded at the Wellcome Collection a couple of weeks ago #obesityisnotachoice www.bbc.com/audio/play/p...
BBC Audio | The Explanation | Weight loss jabs: A medical game changer?
Do weight loss injections have far-reaching benefits beyond weight management?
www.bbc.com
October 19, 2025 at 1:25 PM
'The Evidence' on the BBC World Service where we discussed weight loss medications, which we recorded at the Wellcome Collection a couple of weeks ago #obesityisnotachoice www.bbc.com/audio/play/p...
Why is AI struggling to discover new drugs? via @ft
February 4, 2026 at 3:38 PM
Why is AI struggling to discover new drugs? via @ft
Reposted by Utsav Bali
Dozens of clinical trials are underway trying to change the landscape of autoimmune disease therapy:
Autoimmune Disease, Transformed?
www.science.org
May 20, 2025 at 8:15 PM
Dozens of clinical trials are underway trying to change the landscape of autoimmune disease therapy:
Is there a renaissance in GPCR drug development? www.nature.com/articles/d42...
Is there a renaissance in GPCR drug development?
Sitting at the top of many human signalling cascades, G-protein coupled receptors (GPCRs) play crucial roles in mood, sleep, appetite and every heartbeat. Historically challenging to develop, selectiv...
www.nature.com
January 8, 2025 at 12:01 AM
Is there a renaissance in GPCR drug development? www.nature.com/articles/d42...
Reposted by Utsav Bali
Questions about the GLP-1 agonist class that we might start resolving this year:
Another GLP-1 Year
www.science.org
January 6, 2025 at 8:01 PM
Questions about the GLP-1 agonist class that we might start resolving this year:
Reposted by Utsav Bali
Probability isn’t a property of the world but a tool to navigate uncertainty conceived from subjective judgments and assumptions. #AcademicSky #NurseSky #PhilSky
All of statistics and much of science depends on probability — an astonishing achievement, considering no one’s really sure what it is. 🧪
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Why probability probably doesn’t exist (but it is useful to act like it does)
All of statistics and much of science depends on probability — an astonishing achievement, considering no one’s really sure what it is.
www.nature.com
December 20, 2024 at 6:08 AM
Probability isn’t a property of the world but a tool to navigate uncertainty conceived from subjective judgments and assumptions. #AcademicSky #NurseSky #PhilSky
Reposted by Utsav Bali
Neuroscience students asked us to teach a PRACTICAL course on experimental methods, and it is now on YouTube!
Please like and repost to help us get the word out!
www.youtube.com/playlist?lis...
Lecture 1: Signals and data acquisition
Focusing on hardware, digital/analog I/O, synchronization
🧵
Please like and repost to help us get the word out!
www.youtube.com/playlist?lis...
Lecture 1: Signals and data acquisition
Focusing on hardware, digital/analog I/O, synchronization
🧵
Neuroscience methods - YouTube
Nanocourse: Approaches to Study Neural Circuits This course was taught by Anita Autry, Tiago Gonçalves, and Luke Sjulson at Albert Einstein College of Medici...
www.youtube.com
December 13, 2024 at 11:33 AM
Neuroscience students asked us to teach a PRACTICAL course on experimental methods, and it is now on YouTube!
Please like and repost to help us get the word out!
www.youtube.com/playlist?lis...
Lecture 1: Signals and data acquisition
Focusing on hardware, digital/analog I/O, synchronization
🧵
Please like and repost to help us get the word out!
www.youtube.com/playlist?lis...
Lecture 1: Signals and data acquisition
Focusing on hardware, digital/analog I/O, synchronization
🧵
Reposted by Utsav Bali
Latest from our group in collaboration with Lotte Bjerre Knudsen and other Novo scientists. They developed a GLP-1/Leptin co-agonist that we put through its paces in a number of mouse models to prove that both parts of the molecule matter. More options on the table!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist
Orthogonal murine models demonstrate the bioactivity and neuronal targets of a GLP-1/leptin coagonist in relation to food intake and body weight.
www.science.org
December 4, 2024 at 8:27 PM
Latest from our group in collaboration with Lotte Bjerre Knudsen and other Novo scientists. They developed a GLP-1/Leptin co-agonist that we put through its paces in a number of mouse models to prove that both parts of the molecule matter. More options on the table!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...